Literature DB >> 1692444

Myocardial ischemia, reperfusion and free radical injury.

B R Lucchesi1.   

Abstract

Reperfusion of coronary arteries to limit myocardial ischemic injury and extent of myocardial necrosis is possible by either the use of fibrinolytic therapy, coronary angioplasty or coronary artery bypass surgery. The concept that early reperfusion may salvage jeopardized myocardium is derived from basic experimental studies which purported to demonstrate that the ultimate extent of irreversible myocardial injury could be reduced by reperfusion of the ischemic myocardium within 3 hours from the onset of regional myocardial ischemia. It is firmly established that salvage of ischemic myocardium is dependent on early restoration of blood flow to the myocardium at risk. Despite dependency on reoxygenation for ultimate survival, myocardial tissue that is reperfused and reoxygenated may be subjected to additional injurious insult due to reactive metabolites of oxygen. The cytotoxic species of oxygen are referred to as "oxygen free radicals." Coincident with the influx of inflammatory cells into the reperfused region is an additional loss of otherwise viable myocardial cells. There is strong support for the concept that the polymorphonuclear leukocyte is a contributor to the phenomenon of "reperfusion" or "reoxygenation" injury in the blood perfused heart. This discussion focuses on the role of the neutrophil as a potential contributor to the extension of tissue injury and reviews those interventions, which although in the experimental stage, offer promise of becoming therapeutically important in the future and may help elucidate the mechanisms underlying the potentially deleterious role of the neutrophil in situations involving whole blood reperfusion of the ischemic myocardium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692444     DOI: 10.1016/0002-9149(90)90120-p

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

2.  Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10.

Authors:  B P Chen; C D Wolfgang; T Hai
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  Effect of ascorbic acid supplementation on certain oxidative stress parameters in the post reperfusion patients of myocardial infarction.

Authors:  Pushpa Bhakuni; M Chandra; M K Misra
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

4.  Effects of a Novel Leumedin NPC 15669 on Myocardial Stunning and Preconditioned Infarction Size in Swine.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 5.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

6.  Antiapoptotic effect and inhibition of ischemia/reperfusion-induced myocardial injury in metallothionein-overexpressing transgenic mice.

Authors:  Y James Kang; Yan Li; Xichun Sun; Xiuhua Sun
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

7.  Beneficial effects of bradykinin on porcine ischemic myocardium.

Authors:  R A Tio; T J Tobé; K J Bel; C D de Langen; W H van Gilst; H Wesseling
Journal:  Basic Res Cardiol       Date:  1991 Mar-Apr       Impact factor: 17.165

Review 8.  Pharmacological aspects of calcium antagonism. Short term and long term benefits.

Authors:  W G Nayler
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Effects of thyroid hormone analogue and a leukotrienes pathway-blocker on renal ischemia/reperfusion injury in mice.

Authors:  Najah R Hadi; Fadhil G Al-amran; Ayad A Hussein
Journal:  BMC Nephrol       Date:  2011-12-23       Impact factor: 2.388

10.  Sivelestat attenuates myocardial reperfusion injury during brief low flow postischemic infusion.

Authors:  Sverre E Aune; Steve T Yeh; Periannan Kuppusamy; M Lakshmi Kuppusamy; Mahmood Khan; Mark G Angelos
Journal:  Oxid Med Cell Longev       Date:  2013-05-22       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.